Boston Scientific Expects Synergy To Dominate Drug-Eluting Stents In US
This article was originally published in The Gray Sheet
Executive Summary
Boston Scientific wants to expand the lead against other stents used by interventional cardiologists with the launch of its Synergy drug-eluting stent that they expect will become the workhorse of the industry to handle a broad range of surgeries to treat coronary artery disease. "Our belief is that the target for Synergy is [the] entire market," says Boston Scientific's senior VP and president of its interventional cardiology unit.
You may also be interested in...
Abbott Launches First Fully Absorbing Stent In US Market
Abbott looks to Absorb GT1, the first fully bioresorbable coronary scaffold to gain FDA approval, to help accelerate growth. But it still has yet to be shown superior to conventional drug-eluting stents, and it also has metal stents with bioresorbable polymers to contend with.
Boston Sci Says It Will Be Careful About Resorbable Scaffold Investment
The company announced July 20 the start of its 30-patient, single-arm FAST study assessing its everolimus-eluting scaffold system, but executives says Boston Scientific will be closely considering whether the system warrants long-term investment, considering the promise of its Synergy stent.
Abbott Submits PMA For Absorb Bioresorbable Scaffold
The firm's FDA submission for the first-in-class bioresorbable vascular scaffold was completed in the second quarter, a spokesman said. That appears to be ahead of a prior estimate to submit by the end of 2015.